An abnormally increasedserum PSA concentrationservesasone of the hallmarks of prostatic adenocarcinoma.
The determination of serum PSA concentration, in combination with rectal examination, has been proposed as a screening test for prostatic carcinoma [6, 7] . While support for this particular application is not unanimous at present [8] , investigations into the clinical utility of serum PSA in screening for prostate cancer continue [9, 10] . In contrast to the debate surrounding its putative value as a screeningtool,PSA iswidely acceptedand used to monitor and manage patients with medically established prostate cancer [11] [12] [13] [14] . Serialmonitoring of postprostatectomized patients for increased serum PSA is a common approach for the detection of recurrent or metastatic cancer [15-18/. Furthermore, it has recently been demonstrated that PSA's potency as a marker for diseasemonitoring isgreatlyenhanced when ultrasensitive, as opposed to conventional,assaysare used for itsdetermination [19] [20] [21] . For example, Yu et al. [21] estimate that by using a time-resolved immunofluorometric PSA assay system with a detectionlimitof the order of 10 ng/L, patientrelapsecould be determined several months or years earlierthan by using conventional assays with detection limits of 100 ng/L or higher. Excitement surrounding the power of theseultrasensitive methods has been largely responsibleforthe appearance of commercially available 'third-generation" PSA immunoassays, which have been developed for use on automated analyzers such as Immulite#{174}. Thus, third-generation PSA testing capabilities are ' Nonstandard abbreviations: PSA, prostate-specific antigen; TRIFA, timeresolved immunofluorometric assay; DFP, ditlusinal phosphate; BSA, bovine serum albumin; SA-ALP, streptavidin-conjugated alkaline phosphatase; NHS-LCBiotin, N-hydroxysuccinimide ester of biotin; ACT, a,-antichvmotrvpsin; ER, estrogen receptor; and PR, progesterone receptor.
now available inan automated platform to any clinical biochemistry service laboratory that wishes to use them. There is, in additionto prostate epithelial cells, a growing list of fluids,tissues, and (or) cells that have been found to be associated with PSA immunoreactivity.
The list now includes breast milk, [22] , breast cyst and amniotic fluids [23] , parotid glands [24] , endometrial tissue [25] , normal breast tissue [26] , and various tumor tissues [27] , including those of the breast [28, 29] . In the latter case,PSA immunoreactivitywas associated with steroidhormone receptorpositivity, suggesting a possible role for PSA as a biochemical marker for prognosis and (or) treatment of breastcancer [28, 29] . The PSA concentrationin such tissues is relatively low in comparison with that seen in seminal plasma and sera of patientswith prostatecancer.It follows, therefore, thata very sensitive yet simple assay system is required for the investigation of the association between PSA and the pathobiochemistryof such tissues.
There exist atleast two areaswhere ultrasensitive PSA assays can be of greatvalue:(a)earlywarning of prostatic carcinoma relapseand (b) further elucidationof the association between breastcancer and tumor cytosolPSA concentrations. The first of these is directly relatedto the clinical setting, whereas the second iscurrentlyrestricted to research. The requirement for a very sensitive yet simple and rapidassayforPSA has led us to the development of the time-resolved iminunofluorometric assay (FRIFA) described herein. This report describes our new ultrasensitive PSA assay and contrasts several aspects of its performance to the commercially available Immulite method. [32] . The remainder of the cytosol extract was stored at -70 #{176}C until further analysis. Before these analyses, the frozen extracts were allowed to thaw at 5 #{176}C and vortex-mixed to ensure homogeneity.
Materials and Methods

PSA ASSAYS
Instrumentation
Breast tumor receptor contents. Quantitative analysis of estrogen and progesterone receptors (ER and PR, respectively) was performed with the Abbott enzyme immunoassay kits (Abbott Labs., N. Chicago, IL) as per the manufacturer's instructions.
Other specimens. Aliquots were taken from separated serum specimens thatwere receivedin our laboratoryand identified as being from prostate cancer patients, including postprostatectomized patients, as well as healthy female patients. These aliquots were stored at -70 #{176}C until analysis. 
Results
PERFORMANCE
CHARACTERISTICS OF THE TRIFA
Assay optimization.
The final assay conditions selected were found to be optimal. In brief, we varied factors such as the combinations and quantities of various monoclonal and polyclonal antibodies,the characteristics of the diluents,and the periodsof incubationto obtain the most preciseand sensitive assay performance.
The adoption of a one-step assay approach (i.e., concurrentincubationof specimen and detectionantibody) was made only after an evaluation for high-dose hook effect (see
Calibration curve. Duplicate 50-j.tL calibrators (0, 5, 10, 25, 100, 500, 2000, and 10 000 ng/L PSA) exhibit an overallimprecision in fluorescencereadingsof <5%. The Immulite has a broader dynamic range of 0-20 000 ng/L. We have increased the TRIFA upper dynamic range limit severalfold by decreasing specimen volumes, but at the expense of sensitivity (data not shown).
High-dose hook effect. Given that this version of our PSA TRIFA includes a one-step incubation of analyte and detection antibody, we investigated the possibility of a high-dose hook effect by assaying preparations of free PSA up to 1 000 000 ng/L. As illustrated in Fig. 1 on the Immulite and, in agreement with the manufacturer's claims, no hook effect was observed at 1 000 000 ng/L PSA.
Lower limit of detection. The lowest limit of detection of the TRIFA was determined by analyzing 11 replicates of the zero seminal PSA calibrator.
The PSA concentration, which corresponds to the fluorescence of the zero calibrator plus 2 SD, was calculated to be 1 ng/L. This detection limit corresponds to 50 fg (__106 molecules) of PSA per assay. VVhen we modified this assay to incorporate a lOO-jiL sample volume and include a 200 gil BSA solution as a SA-ALP diluent (to further lower background), the detection limit dropped to 0.3 ng/L (data not shown). The Immulite PSA assay demonstrated a detection limit of 3 ng/L. The biological detectionlimits [34, 35] of the two assay systems were determined by using the estimation of total imprecision observed at 2 ng/L PSA-ACT (see below). We calculate these to be --2 and -4 ng/L for our TRIFA and the Immulite assays, respectively.
Imprecision. The results of our evaluationof imprecisionforthe Immulite third-generationPSA immunoassay and our own TRIFA method are presented in Table I . The imprecision was found to be comparable for the two methods over a wide range of concentrations.
Recovery and equimolarity. To evaluate the recovery of free PSA by our TRIFA method, seminal PSA in 60 gil BSA was used to supplement human sera and BSA (60 gil) to concentrations of 50 and 1000 ng/L. Mean concentrations of 28 ng/L (57%, n = 3) and 463 ng/L (46%, n = 3) were recovered from supplemented female sera. Recoveries from male sera were similar to those from female sera at mean concentrations of22 ng/L (44%, n = 3) and 509 ng/L (51%, n = 3),respectively. The low recovery reflects the binding of PSA to a2-macroglobulin to form a complex thatisnot measurable by the two PSA assays. As expected, recovery of seminal PSA from BSA was practically complete, with mean values of 50 ng/L (100%) and 940 ng/L (94%), respectively. Similar recoveries were obtained for free PSA by the Immulite assay.
We have furtherassayed purifiedpreparationsof free PSA and PSA-ACT complexes in 60 g/L BSA, at concentrations ranging from 10 to 1000 ng/L. The molar response of the new assay to the two forms of PSA was similar (± 10%), confirming the equimolarityof the new assay.Similarresults were obtained with the Immulite.
Linearity. The TRIFA was evaluatedforlinearity over the range 3-400 ng/L by assaying, in triplicate, specimens prepared by mixing human male serum with high PSA concentrations (-410 . Male serum PSA fractionation by HPLC and analysis by our former [19] and current TRIFA methods. ng/L) and serum with low PSA concentrations (-2 ng/L, obtained from a healthy female patient). The equation of the best-fitting regression line is given with Fig. 2 . Another three male serawere alsodilutedfrom twofold to 32-foldwith female serum and reassayed. These sera contained PSA -1000, 500, and 400 ng/L. When the found PSA concentrations were plotted against the expected PSA concentrations, as shown in Fig. 2 , the slopes of the linear regressions were between 1.00 and 1.02 and the intercepts between 6 and 30 ngfL. The correlation coefficients were >0.99 in all three cases, confirming good dilution linearity of the method.
Correlations with patients' sera. We analyzed 42 sera from postprostatectomy patients with our new assay and Immulite. as a percentage of totalPSA, was -10% by the new TRIFA method and 20% by our former method. This discrepancy arises from the greater PSA-ACT immunoreactivity detected by our new ultrasensitive method. In Fig. 5 we present six representative patients who were monitored after radical prostatectomy with the new TRIFA method. These patients were selected to have PSA <100 ngfL after radical prostatectomy, thought to be free of cancer, and are still clinically asymptomatic. Patient a had significant PSA changes by TRIFA 100-200 days after surgery that were not detectable by the Abbott IMx assay. The PSA doubling time of this tumor calculated as described in ref. Correlation data for breast tumor cytosol extract immunoreactivity by the two ultrasensitive PSA assays are illustrated in Fig. 6 . Over all the ranges evaluated, the slope of the best-fitting line is significantly <1, indicating that the TRIFA is estimating more PSA in these specimens than is the Immulite assay (see also TRIFA (7%) and the Immulite (5%) methodologies. The degree of immunoreactivity found by the two methods also differs. The total PSA immunoreactivity of the fractions collected (i.e., free + ACT-PSA) as determined by the Immulite is -60% that determined by our TRIFA method.
Discussion
Ultrasensitive assays for PSA will undoubtedly contribute to opening up new avenues of opportunity in cancer management and research. Many of these opportunities already have been identified. Thus, it appears that such an analytical capability will contribute to the earlier detection of prostate cancer relapse and (or) residual disease in prostatectomized patients as well as the more timely evaluation of response to contemporary therapies (e.g., [21, 34, 35] ). Furthermore, the utility of ultrasensitive PSA analysis is now extending beyond the realm of prostate cancer to thatof breastcancer [28, 29] and probably other cancers [27] .
It is evident that conventional analytical systems for the determination of PSA do not have the detection limits necessary to quantify the relatively low concentrations of this tumor marker as it occurs in breast tumor cytosols and the sera of postprostatectomized men. For example, two popular assay systems for PSA analysis in Canadian service laboratories, the lMx#{174} and AxSYM#{174}, display analytical detection limits of - [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ng/L [35, 36] . It is evident from the data presented here that methods such as the DPC Immulite third-generation PSA assay as well as our own new TRIFA PSA assay are suited to applications that these less sensitive methodologies are not. The assay conditions related here for the TRIFA were selected for optimal sensitivity. In brief, we varied factors such as the combinations and quantities of various monoclonal and polyclonal antibodies, the characteristics of the diluents, and the periods of incubation steps to obtain the most precise and sensitive assay performance.
The optimized assay described in this report differs from our previous assay [19] in two important respects. First, we use two monoclonal murine antibodiesin the presentassay.Second, the detectionantibody and specimen are added togetherto the captureantibody-coatedmicrotiter wells, which allows a one-step incubation. This one-step approach not only simplifies the previous assay procedure [19] but shortens the assaytime by at least2.5 h. The adoption of thisone-step approach was made only after an evaluation for high-dose hook effect. It is evident from Fig. 1 The current optimized method displays even greater sensitivity, with analytical and biological detection limits of 1 and 2 ng/L, respectively, about two times lower than those found forthe Immulite. With a greatersample volume (100 iL insteadof 50 .tL),the detectionlimitfalls to <0.5 ngfL. The significant improvement in the calculatedbiological detection limit of our new TRIFA arises in part from its improved precision. For instance, within-rim imprecisionat 16 ng/L PSA was 21.4% with our former TREFA method [19] . Our new optimized method, on the other hand, has only 18% total imprecision at a nominal PSA-ACT concentration of 2 ng/L (Table 1 ). In comparison, the automated DPC Immulite ultrasensitive assay has a biological detection limit of 4 ng/L PSA and an analytical detection limit of 3 ng/L, a value that is in agreement with the manufacturer's claimed value. Both systems offer significant improvement in sensitivity over most commercially available assay systems, including the Abbott IMx and AxSYM (detectionlimit = 20 ng/L [36] ) and the BMI Enzymun-Test (detectionlimit 50 ng/L). Another important advantage of the present method is the equimolar recognitionof freeand ACT-bound PSA. PSA-ACT is the predominant form of circulating serum PSA (Fig.4) . Thus, an enhanced recognition of this form of PSA should give a greaterability to detectrecurrenceof prostatic cancer during monitoring than would be provided by a low detection limit for freePSA in and of itself. Fig.4 illustrates the greater(-twofold) ability of the new method to detect PSA-ACT in comparison with our former TRIFA method. The benefits of equimolar reactivity for free and ACT-complexed PSA forms in terms of standardization have been reviewed by Graves [37] .
Of considerable importance is the benefit of such highly sensitive PSA assays for the monitoring of prostate cancer patients afterradical surgery.In >50% of thesepatients, PSA is <10 ng/L (thisstudy and [21] )-well below the detectionlimit of conventional assay systems. In these patients, the accurate postsurgical PSA concentration cannot be determined unless ultrasensitive methods such as the methods described in this report are used. We now possess the sensitivity to detect these concentrations and have the potential to detect recurrence at least one, and possibly as many as three, doubling times (i.e., months to years)sooner than previouslypossible [5, 21] .
In this report we describe six patientswhom we monitored for PSA changes over a relatively long period afterradical prostatectomy (Fig.5) . We chose patientswho had at leastone postsurgery PSA value <5 ng/L so that the benefit of monitoring in the ultrasensitive ranges is highlighted.Among the six patients, two (patients b and c) showed no indication of biochemical relapse and their PSA concentrations never exceeded 2.7 ng/L. In contrast, patients a, d, e, and f showed strong evidence of biochemical relapse, because their PSA increased consistently from 0.3 to 185 ng/L (a), 3.3 to 72 ngil (d), 2.4 to 15 ngil (e), and 3.1 to 42 ngil (f). Almost all changes observed could not be seen with conventional assayssuch as the IMx, which have detectionlimits of -20-30 ngil, atleastan order of magnitude inferior to the TRIFA assay described here. We anticipate that our assay, or similar assays developed by compames, will become invaluable tools in detecting early relapse when effective therapies of minimal disease are introduced. Unfortunately, the current capabilities of our assay could not be fully realizedbecause there are no effective therapiesto treat early relapsed prostate cancer. When these therapies become available, we willneed clinical trials to assessthe successrate when the therapyisinstituted atthe earliest possibletime.Until such databecome available, we would recommed, asVesselladid [38] , that the ultrasensitive assays be used only in research settings.
An important application of ultrasensirve PSA assay methodologies relates to the investigation of the relations between breast tumor pathobiochemistry, steroid hormone receptor status,PSA immunoreactivity,and therapeuticoptions.Such investigationsare very likelyto have clinicalrelevance.For instance, hormonal therapyisroutinelyused in the treatmentof breast cancer and is based in large part on the ER and PR characteristics of the breast tumor. Only a fraction of ER-or PR-positive patientsrespond to endocrine therapy.Thus, an important goal of breast cancer research is to further define the prognostic power of available markers and to better tailor treatment modalities on the basis of available markers such as ER and PR status and putative markers such as PSA [28, 29] . Both our TREFA assay and the Immulite third-generation PSA assay demonstrate the ability to reliably detect the low concentrationsof this potentialmarker in extractsof breast tumor cytosols. In this study, we found 28% and 23% positivity for PSA immunoreactivity in breast tumor cytosol extracts by our enhanced TRIFA and the Immulite assays, respectively ( Table  2) . These rates correlate well with that determined previously in this laboratory with our older TRIFA method and a different breastcancer patientseries [28, 29] . The higher positivity rate obtained by our enhanced TRIFA method presumably arises from its higher readingsin comparison with the Immulite by a factor of 20-30%, especially at PSA concentrations <150 ng/mg (Figs. 6 and 7 ). This bias is unlikely to arise only from standardization bias, since our free PSA calibrators were checked against the Immulite calibrators and they agreed to -± 10% or less. We speculate that the bias arises from matrix differences between breasttumor extracts and serum, for which the Immulite is optimized to measure. In general, breast tumor extracts contain1-5 gil protein, whereas serum contains60-80 gil protein.In our TRIFA assay,totalproteindifferences were minimized by adding the sample inparallel with the assaybuffer, which contains 60 gil total protein. Interestingly, comparison of serawith PSA <1000 ngil has shown thatthe Immulite assay measures values -20% higher than TRIFA. Although the absolute values between TRIFA and Immulite for breastcytosolsand serum differ, the correlationwas excellentin both cases.
In contrast to the situation in male sera (Fig. 4) , PSA in female breast tumors exists primarily as the uncomplexed free form (Fig.7) , with the ACT-complexed fraction accounting for only 5% (Immulite) to 7% (TRIFA) of the total PSA in these tumor tissues.
In the series of patients evaluated in this study, ER and PR positivity was associated with women of an older age. Also, breast tumor PSA positivity is preferentially associated with the early stages of breast cancer [28] . Furthermore, PR positivity is recognized as being a favorable prognostic indicator in breast cancer. Thus, further investigation into the clinical utility of PSA immunoreactivity as a prognostic marker in women with breast cancer is indicated by these findings. Such studies are currently under way in our laboratory.
In conclusion, we present data related to the performance and potential utility of third-generation PSA immunoassays inbreast and prostate cancer treatment and research. Experience with such ultrasensitive assays is just beginning to accrue. Nevertheless, we anticipate that the utility of this methodology will soon be established through studiesthat are currentlyunder way in our and other laboratories. 
